Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Elevated sNfL a possible biomarker of recent seizure in epilepsy

April 5, 2024

…nts with seizures in the preceding two months versus those who were seizure-free for >1 year. A total of 27 patients (13%) had abnormally high sNfL concentrations. Elevated sNfL was associated with recent seizures and radiologic evidence of epileptogenic lesions. NfL was weakly correlated with the number of days since the last seizure, and with seizure frequency in the preceding two months. A separate study found that sNfL was generally not elevat…

McDonald criteria 2024: what changes can we expect?

January 30, 2024

…e addressed is the optimal cut-off value (the 40% rule, the 50% rule, the 3- or 6-lesion criteria). As for PRLs, the MAGNIMS group reported that the presence of >1 PRL was highly specific (99.7%) for differentiating CIS/MS from MS mimics or healthy controls (Meaton et al. Mult Scler 2022;28:2212-2220). Specificity was improved (100%) when CVS was present in a PRL. Radiologically isolated syndrome (RIS) is MS in some situations. The RISConsortium r…

First-line anti-CD20 therapy – the new standard of care in MS?

January 25, 2024

…d relapse rate (ARR) was about 46% lower with ocrelizumab versus interferon-β-1a (Rebif) (Hauser et al. N Engl J Med 2017;376:221-234). There was a significant 40% reduction in the rate of 24-week confirmed disability progression (CDP) with ocrelizumab (6.9% vs. 10.5%). The number of gadolinium-enhancing lesions per scan was about 94% lower with ocrelizumab. In a subgroup analysis of OPERA patients with no treatment in the previous two years, ARR…

MS Awards 2023 – Oddities and observations

December 19, 2023

…ding to speed of texting and emoji use (Lam et al. Eur J Neurol 2022;29:522-534). In the Lam study, the combined metric of emoji sentiments and the length of words was a better measure of disability worsening than the EDSS. HIPPOcratic Award Hippocrates was keen on “riding’s healing rhythm”. And a new systematic review has found that horse-assisted interventions (hippotherapy) can benefit a range of neurological conditions (Mittly et al. Syst Rev…

The year in review – 2023

December 12, 2023

…in its two EVOLUTION phase III trials (www.emdgroup.com/en/news/evobrutinib-phase-lll.html). The annualized relapse rate for evobrutinib in the two studies (0.11, 0.15) was similar to what was seen with teriflunomide (0.11, 0.14). Evobrutinib performed as expected: the unadjusted ARR was the same in the phase II trial (0.11 vs. 0.14 for DMF) (Montalban et al. N Engl J Med 2019;380:2406-2417) and the same (0.11) in the 192-week open-label extension…